Compare PPLC & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PPLC | ERNAW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 6546 | 5 |
| Industry | Electric Utilities: Central | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | PPLC | ERNAW |
|---|---|---|
| Price | $48.41 | $0.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 86.2K | 10.5K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.99 | $0.02 |
| 52 Week High | $52.57 | $0.23 |
| Indicator | PPLC | ERNAW |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 36.08 |
| Support Level | $48.83 | $0.02 |
| Resistance Level | $52.16 | $0.06 |
| Average True Range (ATR) | 0.83 | 0.03 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 75.34 | 0.00 |
PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.